Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a strong-buy rating in a report published on Sunday,Wall Street Zen reports.

Several other research firms have also recently weighed in on REGN. Guggenheim raised their price target on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Leerink Partners upped their price objective on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a report on Monday, August 17th. Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research report on Tuesday, July 7th. Wells Fargo & Company increased their target price on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Finally, Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Fourteen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $802.18.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $784.85 on Friday. The company’s fifty day simple moving average is $766.83 and its two-hundred day simple moving average is $720.24. Regeneron Pharmaceuticals has a 52 week low of $541.00 and a 52 week high of $859.34. The stock has a market cap of $80.81 billion, a P/E ratio of 19.40, a PEG ratio of 1.54 and a beta of 0.20. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the business posted $12.81 earnings per share. Analysts predict that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Insider Buying and Selling

In other news, EVP Marion Mccourt sold 1,131 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the sale, the executive vice president directly owned 12,003 shares of the company’s stock, valued at $10,291,252.17. This trade represents a 8.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at approximately $512,550. This trade represents a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 4,146 shares of company stock valued at $3,432,488. 6.97% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of REGN. Tidal Investments LLC raised its stake in shares of Regeneron Pharmaceuticals by 10.7% in the second quarter. Tidal Investments LLC now owns 43,896 shares of the biopharmaceutical company’s stock valued at $27,371,000 after acquiring an additional 4,244 shares during the period. National Pension Service boosted its stake in shares of Regeneron Pharmaceuticals by 2.2% during the 2nd quarter. National Pension Service now owns 379,815 shares of the biopharmaceutical company’s stock worth $236,830,000 after purchasing an additional 8,264 shares during the period. Krensavage Asset Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 50.0% during the 2nd quarter. Krensavage Asset Management LLC now owns 6,000 shares of the biopharmaceutical company’s stock worth $3,741,000 after purchasing an additional 2,000 shares during the period. Engineers Gate Manager LP grew its holdings in Regeneron Pharmaceuticals by 4,309.4% during the 2nd quarter. Engineers Gate Manager LP now owns 15,918 shares of the biopharmaceutical company’s stock valued at $9,926,000 after purchasing an additional 15,557 shares during the last quarter. Finally, Cidel Asset Management Inc. raised its position in Regeneron Pharmaceuticals by 7.8% in the 2nd quarter. Cidel Asset Management Inc. now owns 775 shares of the biopharmaceutical company’s stock worth $483,000 after purchasing an additional 56 shares during the period. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.